Flourtown, Pennsylvania Clinical Trials

A listing of Flourtown, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

mental state examination
apolipoprotein e4
mini-mental state examination
alzheimer's disease
Accepts healthy volunteers
The Clinical Trial Center, LLC
 (4.6 away) Contact site
  • 32 views
  • 20 Sep, 2024
  • +126 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

macitentan 10 mg
ventricular septal defects
left ventricular end-diastolic pressure
ventricular septal defect
septal defect
Lankenau Medical Center
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +210 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

neutrophil count
lymphocytic leukemia
17p deletion
absolute neutrophil count
obinutuzumab
Consultants in Medical Oncology and Hematology, P.C.
 (6.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +50 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

cancer metastatic
locally advanced breast cancer
metastasis
oestrogen receptor positive breast cancer
cancer
Investigational Site Number 8400001
 (9.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +130 other locations
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

maintenance therapy
metastasis
cancer therapy
cancer
carboplatin
Fox Chase Cancer Center
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +15 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

antiandrogen therapy
orchiectomy
prednisone
metastasis
cancer
Research Site
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +106 other locations
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

neuropathy
metastasis
luteinizing hormone
cancer
lymphadenopathy
Fox Chase Cancer Center
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +17 other locations
Clinician Communication About Sexual Health

The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.

Fox Chase Cancer Center
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate …

blood test
covid-19
Temple Univ School of Med
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

pao2
headache
myalgia
FIO2
cough
Temple University
 (7.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations